Forgetting a name once in a while is normal. But when memory slips start piling up, many people wonder the same thing. Is this just aging, or the start of something more serious?
A new consensus document from Spain’s neurogeriatrics specialists puts early detection and a multimodal prevention plan up front. Multimodal means combining tools like lifestyle changes, cognitive support, and medical nutrition. It also highlights Souvenaid as a clinical nutrition option for early Alzheimer-related cognitive impairment that can overlap with mild cognitive impairment.
Mild cognitive impairment explained
Mild cognitive impairment is often described as a middle step between typical aging and dementia. The key difference is that a person can notice changes in memory or thinking, but still manages day-to-day life without losing independence. Some people stay stable for years, and a few improve.
In a Spanish language statement, neurologist María José Gil at Hospital Universitario Clínico San Carlos in Madrid described the condition as involving “memory losses, behavioral changes, changes in executive function or language,” while daily independence is still preserved. Executive function is the brain’s planning and self-control system. In plain terms, someone might struggle more with planning or finding words, but still pays bills and gets around on their own.
How common is it? Recent coverage of the release put it at about three in ten people over 65 in Spain. An earlier 2019 press release estimated it closer to 15% in that age group, showing how hard it can be to pin down the condition with one number.
Why early screening matters
The document’s first big message is simple. Catch cognitive decline early, when there is still time to slow it down and plan support.
That can include basic screening tools, which are short tests that check memory, attention, and problem solving. They are not a final diagnosis, but they can flag when someone should get a fuller evaluation.
It also means thinking about the people around the patient. Cristina Fernández García, head of Neurology at Hospital Universitario La Moraleja in Madrid, said families carry an emotional, physical, and economic load that should be considered when planning care. For many households, the stress is not abstract, it is daily.
A long list of risk factors people can change
Prevention is getting so much attention partly because of the size of the opportunity. The consensus points to evidence suggesting that acting on modifiable risks could prevent or delay up to 40% of dementia cases.
Those risks are not mysterious. They include high blood pressure, diabetes, obesity, smoking, depression, hearing loss, and social isolation, plus head injuries and air pollution.
In a Spanish language statement, Carmen Terrón, a neurologist at Hospital Virgen del Rosario in Madrid and coordinator of the neurogeriatrics group, said “reducing dementia risk is crucial.” The document also notes that people with low physical activity have about a 30% higher risk of dementia, a reminder that movement is not just about muscles, it is also about brain health. Even small changes, like breaking up long sitting periods, can be part of the plan.
The new role for medical nutrition
The consensus does not frame nutrition as a trendy add-on. It treats it as clinical nutrition, meaning targeted nutrition used under medical supervision for specific health needs.
Sagrario Manzano, a neurologist at Hospital Universitario Infanta Leonor in Madrid who also teaches at Complutense University of Madrid, said “medical foods” are formulated to meet dietary needs that cannot be handled by normal diet changes alone. In practical terms, they are meant for patients who need specific nutrients, with a clinician guiding how and when they are used.
In that context, the document notes that Souvenaid is the only authorized medical food in Spain for cognitive impairment associated with early Alzheimer’s disease. Souvenaid is produced by Danone Nutricia, and the company says it is continuing research in medical nutrition.
What Souvenaid’s studies have shown
So what does the evidence look like when you zoom in? The document describes four randomized clinical trials comparing Souvenaid with a placebo, meaning a look-alike drink without the active nutrient mix, in people with Alzheimer’s dementia from mild to moderate.
In moderate dementia, the trials did not show meaningful improvements in overall cognitive or daily function measures. In mild dementia, the overall results were also not clearly better, but some tests showed positive differences in memory and attention.
The document also cites brain scan research suggesting healthier connectivity between brain regions, which researchers link to synapses, the connection points that help brain cells communicate. That is a promising idea, but it is also the kind of detail that needs careful follow-up in larger studies.
What the research says, and what it does not
A separate clinical trial called the LipiDiDiet study looked at people with “prodromal” Alzheimer’s disease, which is an early stage when symptoms are emerging. It did not find clear benefits on overall cognitive performance or progression to dementia, but it did report better memory scores and slower shrinkage in the hippocampus, a brain area closely tied to memory, over three years.
This is where nuance matters. A Cochrane review published in 2020 concluded that Souvenaid probably does not reduce the risk of progressing to dementia in prodromal Alzheimer’s disease, and it described the wider evidence as still controversial.
At the same time, prevention experts continue to emphasize that nutrition is only one piece of a bigger puzzle. The 2020 Lancet Commission report estimated that around 40% of dementias could be prevented or delayed by addressing risks across a person’s life, and its 2024 update raised that estimate by adding vision loss and high LDL cholesterol. So the takeaway is not that one product “solves” cognitive decline, but that combined strategies may buy time and that memory worries are worth raising with a doctor.
The main consensus document has been published by the Spanish Society of Neurology.
